Prognostic value of the Scottish Inflammatory prognostic Score in patients with NSCLC expressing PD-L1&#xa0;&#x2265;&#xa0;50&#xa0;% progressing on first-line pembrolizumab

Lung, Respiratory and Thoracic Cancer

Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression

Lung Cancer

Miyakoshi J, Yoshida T, Kashima J, Shirasawa M, Torasawa M, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Shiraishi K, Kohno T, Yamamoto N, Yatabe Y, Suzuki T, Ohe Y

doi: 10.1016/j.lungcan.2024.107788

Lung, Respiratory and Thoracic Cancer

First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17

Eur J Cancer

Mark M, Froesch P, Gysel K, Rothschild SI, Addeo A, Ackermann CJ, Chiquet S, Schneider M, Ribi K, Maranta AF, Bastian S, von Moos R, Joerger M, Früh M, Swiss Group for Clinical Cancer Research (SAKK)

doi: 10.1016/j.ejca.2024.113600

Genitourinary Cancer

PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort

Eur J Cancer

Naffrichoux J, Poupin P, Pouillot W, Linassier C, Rioux-Leclercq N, De Vries-Brilland M, Mourey L, Laguerre B, Oudard S, Gross-Goupil M, Mousset C, Gravis G, Rolland F, Moise L, Emambux S, Vassal C, Zanetta S, Penel N, Albiges L, Fromont G, Cancel M

doi: 10.1016/j.ejca.2024.114121

Lung, Respiratory and Thoracic Cancer

Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01

Eur J Cancer

Tanaka H, Makiguchi T, Tozuka T, Kawashima Y, Oba T, Tsugitomi R, Koyama J, Tambo Y, Ogusu S, Saiki M, Gyotoku H, Hasegawa T, Miyauchi E, Sonoda T, Saito R, Nakatomi K, Sakatani T, Kudo K, Tsuchiya-Kawano Y, Nishio M

doi: 10.1016/j.ejca.2024.115117

EHA 2024

Leukemia

Real-world study showed that initiating the next treatment was significantly more common among patients treated with first-line acalabrutinib versus first-line ibrutinib

Lung, Respiratory and Thoracic Cancer

Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed

Eur J Cancer

Leonetti A, Perrone F, Puntoni M, Maglietta G, Bordi P, Bria E, Vita E, Gelsomino F, De Giglio A, Gelibter A, Siringo M, Mazzoni F, Caliman E, Genova C, Bertolini F, Guaitoli G, Passiglia F, Delcuratolo MD, Montrone M, Cerea G, Pasello G, Roca E, Belluomini L, Cecere FL, Guida A, Manzo A, Adamo V, Rastelli F, Bulotta A, Citarella F, Toschi L, Zoratto F, Cortinovis DL, Berardi R, Follador A, Carta A, Camerini A, Salerno F, Silva RR, Baldini E, Cortellini A, Brighenti M, Santoni M, Malorgio F, Caminiti C, Tiseo M

doi: 10.1016/j.ejca.2024.114006

Lung, Respiratory and Thoracic Cancer

Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels

Lung Cancer

Sun L, Handorf EA, Zhou Y, Borghaei H, Aggarwal C, Bauman J

doi: 10.1016/j.lungcan.2024.107510

Lung, Respiratory and Thoracic Cancer

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial

Lancet Oncol

Wu YL, Guarneri V, Voon PJ, Lim BK, Yang JJ, Wislez M, Huang C, Liam CK, Mazieres J, Tho LM, Hayashi H, Nhung NV, Chia PL, de Marinis F, Raskin J, Zhou Q, Finocchiaro G, Le AT, Wang J, Dooms C, Kato T, Nadal E, Hin HS, Smit EF, Wermke M, Tan D, Morise M, O'Brate A, Adrian S, Pfeiffer BM, Stroh C, Juraeva D, Strotmann R, Goteti K, Berghoff K, Ellers-Lenz B, Karachaliou N, Le X, Kim TM, INSIGHT 2 investigators

doi: 10.1016/S1470-2045(24)00270-5

SPECIAL REPORT

Genitourinary Cancer

Oncology · Hematology

Prognostic value of the Scottish Inflammatory prognostic Score in patients with NSCLC expressing PD-L1 ≥ 50 % progressing on first-line pembrolizumab

Related content

Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression

First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17

PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort

Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01

Real-world study showed that initiating the next treatment was significantly more common among patients treated with first-line acalabrutinib versus first-line ibrutinib

Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed

Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial

EAU Annual Congress 2024: adjuvant therapy for high-risk muscle-invasive urothelial carcinoma with PD-L1 expression ≥ 1